Literature DB >> 4758839

Pharmacodynamics of cefazolin in the presence of normal and impaired renal function.

M F Rein, F B Westervelt, M A Sande.   

Abstract

The excretion of cefazolin, a new cephalosporin antibiotic, was studied in subjects with normal and impaired renal function. Twelve subjects with creatinine clearances ranging from 0 to 144 ml per min per 1.73 m(2) were given a single 500-mg intramuscular dose of cefazolin. Serum and urine levels were determined at intervals by agar diffusion. Peak serum levels in normals ranged from 44 to 70 mug/ml and occurred 30 to 60 min after injection. The mean serum half-life in normals was 1.6 h, and this was prolonged from 20 to 40% by simultaneous administration of probenecid. The total elimination constant varied linearly with the creatinine clearance in patients with renal impairment. The serum half-life in anephric patients was about 42 h. The fractional clearance of the drug varied directly with the serum level. Peak urine levels ranged from 60 to over 2,000 mug/ml, and more than 90% of the dose was recovered in the urine of normals during the first 24 h. The data suggest that cefazolin is cleared primarily by the glomerulus, with tubular and biliary secretion playing a secondary role.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4758839      PMCID: PMC444558          DOI: 10.1128/AAC.4.3.366

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Cefazolin, a new semisynthetic cephalosporin antibiotic. II. In vitro and in vivo antimicrobial activity.

Authors:  M Nishida; T Matsubara; T Murakawa; Y Mine; Y Yokota
Journal:  J Antibiot (Tokyo)       Date:  1970-03       Impact factor: 2.649

2.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

3.  In vitro and in vivo evaluation of cefazolin, a new cephalosporin C derivative.

Authors:  M Nishida; T Matsubara; T Murakawa; Y Mine; Y Yokota; S Kuwahara; S Goto
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

4.  Apparent effect of probenecid on the distribution of penicillins in man.

Authors:  M Gibaldi; M A Schwartz
Journal:  Clin Pharmacol Ther       Date:  1968 May-Jun       Impact factor: 6.875

5.  Cefazolin, a new semisynthetic cephalosporin antibiotic. 3. Absorption, excretion and tissue distribution in parenteral administration.

Authors:  M Nishida; T Matsubara; T Murakawa; Y Mine; Y Yokota; S Goto; S Kuwahara
Journal:  J Antibiot (Tokyo)       Date:  1970-04       Impact factor: 2.649

6.  Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients.

Authors:  W M Kirby; J B De Maine; W S Serrill
Journal:  Postgrad Med J       Date:  1971-02       Impact factor: 2.401

7.  Pharmacokinetics of cephalexin in renal insufficiency.

Authors:  C Regamey; L Humair
Journal:  Postgrad Med J       Date:  1971-02       Impact factor: 2.401

8.  Blood, urine and tissue concentrations of the cephalosporin antibiotics in normal subjects.

Authors:  R S Griffith; H R Black
Journal:  Postgrad Med J       Date:  1971-02       Impact factor: 2.401

9.  Cephaloridine versus cephalothin: relation of the kidney to blood level differences after parenteral administration.

Authors:  S B Tuano; J L Brodie; W M Kirby
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1966

10.  Cefazolin, a new semisynthetic cephalosporin antibiotic. I. Synthesis and chemical properties of cefazolin.

Authors:  K Kariyone; H Harada; M Kurita; T Takano
Journal:  J Antibiot (Tokyo)       Date:  1970-03       Impact factor: 2.649

View more
  11 in total

1.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

2.  Determination of appropriate weight-based cutoffs for empiric cefazolin dosing using data from a phase 1 pharmacokinetics and safety study of cefazolin administered for surgical prophylaxis in pediatric patients aged 10 to 12 years.

Authors:  Michael L Schmitz; Jeffrey L Blumer; Wes Cetnarowski; Christopher M Rubino
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

3.  Wound Penetration of Cefazolin, Ciprofloxacin, Piperacillin, Tazobactam, and Vancomycin During Negative Pressure Wound Therapy.

Authors:  Matthew P Rowan; Krista L Niece; Julie A Rizzo; Kevin S Akers
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-02-01       Impact factor: 4.730

Review 4.  Cephalosporin-probenecid drug interactions.

Authors:  G R Brown
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of probenecid.

Authors:  R F Cunningham; Z H Israili; P G Dayton
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

6.  Pharmacology of intraperitoneal cefazolin in patients undergoing peritoneal dialysis.

Authors:  D Kaye; N Wenger; B Agarwal
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

7.  Metabolic fate of SCE-1365, a new broad-spectrum cephalosporin, after parenteral administration to rats and dogs.

Authors:  S Tanayama; K Yoshida; K Adachi; T Kondo
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

8.  Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis.

Authors:  Darren M Roberts; Dwarakanathan Ranganathan; Steven C Wallis; Julie M Varghese; Adrian Kark; Jeffrey Lipman; Jason A Roberts
Journal:  Perit Dial Int       Date:  2016-01-13       Impact factor: 1.756

9.  Influence of probenecid on serum levels and urinary excretion of cinoxacin.

Authors:  N Rodriguez; P O Madsen; P G Welling
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

10.  Intravenous (IV) cefazolin with oral probenecid: A novel daily regimen for the management of Methicillin Sensitive Staphylococcus aureus (MSSA) bacteremia in a patient with renal dysfunction.

Authors:  Sunish Shah; Marjorie Golden; Jeffrey E Topal; Dayna McManus
Journal:  IDCases       Date:  2020-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.